Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2020
This is a multicenter non-inferiority study, designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years.
Epistemonikos ID: e12f37c2f78d23b016f353bc89ad7fd6bb360d34
First added on: Mar 31, 2022